Pediatric hepatocellular carcinoma (HCC) and fibrolamellar carcinoma are rare, aggressive forms of liver cancer that typically affect adolescents and young adults.
Immunotherapy research offers new hope for children with primary liver carcinomas retrieved 30 August 2024 from https://medicalxpress.com/news/2024-08-immunotherapy-children-primary-liver-carcinomas.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Managing early stages of abortion care at home after 12 weeks is safe and reduces time spent in hospital, study finds22 hours ago
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Neoadjuvant immunotherapy may facilitate surgery, improve outcomes for patients with high-risk liver cancerPatients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery—including those who would not have been eligible for surgery by conventional criteria—had similar outcomes to patients who received surgery upfront, according to results from a retrospective study published in Cancer Research Communications.
Read more »
Neoadjuvant immunotherapy yields comparable outcomes in high-risk liver cancer surgeryPatients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery-;including those who would not have been eligible for surgery by conventional criteria-;had similar outcomes to patients who received surgery upfront, according to results from a retrospective study.
Read more »
Hydrogel device enables painless transdermal delivery of nucleic acids for cancer immunotherapyNucleic acid (NA)-based medicine has been a focal point of research over the past two decades and has shown immense promise for both therapeutics and vaccines. The rapid development and deployment of NA-based vaccines during the COVID-19 pandemic underscored their potential.
Read more »
New targets for improved cancer immunotherapyIn the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors.
Read more »
Tpex cells: A game-changer in targeted tumor immunotherapyProgenitor exhausted CD8+ T (Tpex) cells have emerged as a pivotal component in tumor immunotherapy due to their unique ability to self-renew and rapidly proliferate. These cells have shown promise in expanding and differentiating into functional exhausted CD8+ T cells, significantly enhancing clinical outcomes.
Read more »
New work validates targets for personalized cancer immunotherapyWhat are the characteristics of a cancer cell that are recognized by the immune system? Knowledge of the potential target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies.
Read more »